Coach vs. Kors: Bat...
Health Care: Drugs
Alkermes PLC (ALKS: NASDAQ)
$15.12 -0.50 | -3.20%
06/01/12 - 04:00 PM ET
Ratio Comparisons
| Company | Industry | S&P 500 | |
| Valuation Ratios | |||
|---|---|---|---|
| P/E Ratio (TTM) | n.a. | n.a. | 17.70 |
| P/E High - Last 5 Yrs | n.a. | n.a. | 67.70 |
| P/E Low - Last 5 Yrs | n.a. | n.a. | 12.50 |
| Beta | 0.82 | 0.94 | 0.98 |
| Price to Sales (TTM) | 5.05 | 4.21 | 1.42 |
| Price to Book (MRQ) | 2.31 | 3.38 | 2.41 |
| Price to Tangible Book (MRQ) | 13.75 | -8.72 | 5.08 |
| Price to Cash Flow (TTM) | -98.50 | 274.70 | 9.80 |
| Price to Free Cash Flow (TTM) | -3.80 | -63.90 | 17.40 |
| Dividends | |||
| Dividend Yield (%) | 0.00 | 0.00 | 2.10 |
| Dividend Yield - 5 Yr Avg (%) | n.a. | 1.20 | 2.20 |
| Dividend 5 Yr Growth Rate (%) | n.a. | 23.61 | -0.76 |
| Payout Ratio (TTM) | 0.00 | n.a. | 30.00 |
| Sales (MRQ) vs Qtr 1 Yr Ago (%) | 155.10 | 37.70 | 11.80 |
| Sales (TTM) vs TTM 1 Yr Ago (%) | 108.90 | 1.60 | 9.20 |
| Growth Rates (%) | |||
| Sales - 5 Yr Growth Rate (%) | 3.07 | 7.01 | 1.79 |
| EPS (MRQ) vs Qtr 1 Yr Ago (%) | n.a. | 225.80 | 17.50 |
| EPS (TTM) vs TTM 1 Yr Ago (%) | n.a. | 225.80 | 17.50 |
| EPS - 5 Yr Growth Rate (%) | n.a. | n.a. | -1.66 |
| Capital Spending - 5 Yr Growth Rate (%) | 41.53 | 4.51 | -1.17 |
| Financial Strength | |||
| Quick Ratio (MRQ) | 3.20 | 1.40 | 1.10 |
| Current Ratio (MRQ) | 3.80 | 2.40 | 1.60 |
| LT Debt to Equity (MRQ) | 0.52 | 0.90 | 0.82 |
| Total Debt to Equity (MRQ) | 0.52 | 0.91 | 0.96 |
| Interest Coverage (TTM) | n.a. | 0.70 | 5.50 |
| Profitability Ratios (%) | |||
| Gross Margin (TTM) | 73.10 | 54.60 | 46.90 |
| Gross Margin - 5 Yr Avg | 82.30 | 54.70 | 47.70 |
| EBITD Margin (TTM) | 1.40 | 17.90 | 18.90 |
| EBITD - 5 Yr Avg | -4.31 | 0.00 | 0.00 |
| Pre-Tax Margin (TTM) | -29.30 | -1.60 | 12.10 |
| Pre-Tax Margin - 5 Yr Avg | 7.40 | -1.20 | 10.30 |
| Management Effectiveness (%) | |||
| Net Profit Margin (TTM) | -0.29 | -0.01 | 0.09 |
| Net Profit Margin - 5 Yr Avg | 7.50 | -1.20 | 7.00 |
| Return on Assets (TTM) | -7.90 | -0.40 | 3.10 |
| Return on Assets - 5 Yr Avg | 2.70 | -0.60 | 2.50 |
| Return on Investment (TTM) | -8.80 | -0.60 | 7.90 |
| Return on Investment - 5 Yr Avg | 3.20 | -0.80 | 6.50 |
| Efficiency | |||
| Revenue/Employee (TTM) | 324,981.00 | 379,608.00 | 449,376.00 |
| Net Income/Employee (TTM) | -94,732.00 | -4,557.00 | 39,003.00 |
| Receivable Turnover (TTM) | 6.50 | 6.60 | 7.60 |
| Inventory Turnover (TTM) | 3.50 | 2.90 | 8.30 |
| Asset Turnover (TTM) | 0.40 | 0.50 | 0.40 |
Portfolios with ALKS
- Portfolio NameUser Type
- ContributorEarnings Short Squeeze Play...
- ContributorStocks With Big Insider Buy...
- UserInvestments
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Rising On Unusual Vo...
- ContributorBreakout Stocks Of The Week...
- Usergterryburns
- Usermitetwo Portfolio 1
- ContributorBreakout Stocks Of The Week...
- Contributor10 Biotech Stocks Facing FD...
Latest ALKS Headlines from TheStreet
- Cramer's 'Mad Money' Recap: Housing Comeback 05.10.12 | 08:05 pm
- 5 Stocks Insiders Love Right Now 05.02.12 | 11:05 am
- 8 Stocks Rising on Monster Volume 03.28.12 | 12:03 pm
- Insiders Trading TZYM, ALKS, CAKE 03.15.12 | 08:03 am
- The Curse of Amylin's Diabetes Drug Approval 02.06.12 | 08:02 am
- PharMerica, Amylin: After-Hours Trading 01.27.12 | 06:01 pm
- Third Time's The Charm for Approval of Amylin Diabetes Drug 01.27.12 | 03:01 pm
- 7 Stocks Rising on Huge Volume 01.25.12 | 02:01 pm
- UBS: 6 Specialty Pharma Picks to Watch 01.21.12 | 07:01 am
- Biotech Lessons Learned From JPM 2012 01.13.12 | 06:01 am
Press Releases for ALKS
- Alkermes’ Corporate Presentation To Be Webcast At Two Upcoming Conferences - Business Wire 05.31.12 | 07:05 am
- Alkermes Announces Results From Phase 2 Study Of ALKS 37 For Treatment Of Opioid-Induced Constipation - Business Wire 05.30.12 | 04:05 pm
- Alkermes Presents Positive Clinical Data Of ALKS 5461 At 52nd Annual New Clinical Drug Evaluation Unit Meeting - Business Wire 05.29.12 | 04:05 pm
- Alkermes Plc Completes Secondary Offering Of 24,150,000 Ordinary Shares Held By Elan - Business Wire 03.13.12 | 11:03 am
- Alkermes Plc Prices Secondary Offering Of 21,000,000 Ordinary Shares Held By Elan - Business Wire 03.08.12 | 09:03 am
- Alkermes Plc Announces A Secondary Offering Of 13,900,000 Ordinary Shares Held By Elan - Business Wire 03.07.12 | 04:03 pm
- Alkermes Appoints Mark Stejbach As Chief Commercial Officer - Business Wire 03.05.12 | 07:03 am
- Alkermes’ Corporate Presentation To Be Webcast At The Cowen & Company 32nd Annual Health Care Conference - Business Wire 02.27.12 | 04:02 pm
- Alkermes Files Resale Shelf Registration In Connection With Elan Shareholder Agreement - Business Wire 02.16.12 | 04:02 pm
- BYDUREONâ¢, First And Only Once-Weekly Type 2 Diabetes Treatment, Now Available In U.S. Pharmacies - PR Newswire 02.13.12 | 08:02 am
Partner Headlines for ALKS
- Healthcare Biz Recap: Teva's Counterfeit Problem, Hopes for Bristol-Myers - Wall St. Cheat Sheet 05.30.12 | 07:05 am
- Alkermes Earnings Call Insights: Adjusted EBITDA, VIVITROL - Wall St. Cheat Sheet 05.29.12 | 01:05 pm
- 9 High-Liquidity Mid Caps Poised For Growth - Seeking Alpha 05.28.12 | 08:05 am
- Long Undervalued, Is Alkermes Still A Bargain? - Seeking Alpha 03.30.12 | 09:03 am
- Kinetics Hedge Fund's Top Undervalued Picks - Seeking Alpha 03.23.12 | 05:03 pm
- Elan Sells 76% Stake in Alkermes - Analyst Blog - Zacks 03.16.12 | 05:03 pm
- Alkermes Announces a Secondary Offering of 13,900,000 Ordinary Shares Held by Elan - Benzinga 03.07.12 | 04:03 pm
- Bydureon Physician Survey: Results Yield Insight Into Launch Trajectory - Seeking Alpha 02.22.12 | 08:02 am
- The Zacks Analyst Blog Highlights: Charles Schwab, E*TRADE Financial, TD Ameritrade Holding, Amylin Pharmaceuticals and Alkermes plc - Press Releases - Zacks 02.16.12 | 09:02 am
- Analyzing Friday's Noteworthy Insider Buys And Sells - Seeking Alpha 02.12.12 | 07:02 am
